 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...496497498499500501502503504505506507508 |
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Enrollment open: S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Sep 26, 2011
P2, N=155, Recruiting, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting
- |||||||||| evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
New P3 trial, Combination therapy, Metastases: TH-CR-406: A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 22, 2011
P3, N=620, Active, not recruiting, Sponsor: Threshold Pharmaceuticals
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer (clinicaltrials.gov) - Sep 14, 2011
P=N/A, N=41, Completed, Sponsor: University of Washington
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients (clinicaltrials.gov) - Sep 13, 2011
P=N/A, N=23, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=18 --> 23
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients (clinicaltrials.gov) - Sep 13, 2011
P=N/A, N=23, Completed, Sponsor: M.D. Anderson Cancer Center
N=18 --> 23 Active, not recruiting --> Completed
- ||| cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
New P2/3 trial: Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients (clinicaltrials.gov) - Sep 12, 2011
P2/3, N=40, Completed, Sponsor: Dexa Medica Group
- Zolinza (vorinostat) / Merck (MSD)
Enrollment open, Combination therapy: Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) (clinicaltrials.gov) - Sep 11, 2011
P1/2, N=30, Recruiting, Sponsor: University Hospital Freiburg
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- New P2 trial, Combination therapy: An Open-Label Phase II Study of the Safety and Efficacy of Doxorubicin and Cyclophosphamide in Combination with Bortezomib, Lenalidomide, and Dexamethasone for Treatment of Patients with Newly Diagnosed Multiple Myeloma (EUDRACT) - Sep 4, 2011
P2, N=30, Ongoing, Sponsor: Vejle Hospital
- cisplatin / Generic mfg., cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma (clinicaltrials.gov) - Aug 31, 2011
P2, N=140, Completed, Sponsor: University of Arkansas
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 25, 2011
P2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| MK-4214 (filgrastim biosimilar) / Merck (MSD)
New P3 trial: A Phase III Randomized, Double-Blind, Active-Controlled Clinical Trial to Study the Efficacy and Safety of MK-4214 (filgrastim) and Neupogen (EUDRACT) - Aug 24, 2011
P3, N=32, Ongoing, Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
- ||||| seribantumab (MM-121) / Elevation Oncology
New P2 trial: A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer (clinicaltrials.gov) - Aug 18, 2011
P2, N=200, Active, not recruiting, Sponsor: Merrimack Pharmaceuticals
- pevonedistat (MLN4924) / Takeda, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Biomarker, New P1/2 trial: MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma (clinicaltrials.gov) - Aug 10, 2011
P1/2, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Biomarker, New P2 trial, Combination therapy, Metastases: A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) (clinicaltrials.gov) - Aug 9, 2011
P2, N=100, Active, not recruiting, Sponsor: Genentech
- |||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open, Combination therapy: A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) (clinicaltrials.gov) - Aug 9, 2011
P3, N=1400, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., capecitabine / Generic mfg.
New P2/3 trial: AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer (clinicaltrials.gov) - Aug 8, 2011
P2/3, N=300, Recruiting, Sponsor: Peking Union Medical College Hospital
- bortezomib / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial termination, Metastases: Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer (clinicaltrials.gov) - Aug 7, 2011
P2, N=4, Terminated, Sponsor: University of Wisconsin, Madison
Not yet recruiting --> Recruiting Suspended --> Terminated; no additional funding
- | Rituxan (rituximab) / Roche
New P2 trial: S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Aug 7, 2011
P2, N=180, Recruiting, Sponsor: Southwest Oncology Group
- Campath (alemtuzumab) / Sanofi
Enrollment closed, IO biomarker: CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas (clinicaltrials.gov) - Aug 7, 2011
P1, N=24, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Suspended --> Terminated; no additional funding Recruiting --> Active, not recruiting